@Resolvemasslabs profile picture
ResolveMass Laboratories Inc. @Resolvemasslabs

At ResolveMass, we specialize in analytical testing, custom synthesis, impurity profiling, and advanced method development and mass spectrometry services.

Joined August 2025
  • Tweets 136
  • Following 6
  • Followers 8
Photos and videos
🚀 mRNA therapeutics demand specialized bioanalysis. See how ResolveMass solved LNP interference & complex matrix challenges for IND success. Read more: resolvemass.ca/bioanalytical… #mRNATherapeutics #AnalyticalTesting

Case Study: Bioanalytical Method Development for a First-in-Class mRNA Therapeutic with Complex...

Introduction: Bioanalytical method development for mRNA therapeutics is fundamentally different from conventional drug modalities — and getting it wrong at […]

resolvemass.ca
1
4
🔬 API sameness is more than structure. Impurity profiles are key to proving quality, safety & equivalence. Learn how regulators assess APIs. Read more: resolvemass.ca/impurity-prof… #ImpurityProfiling #PharmaceuticalScience

Impurity Profiles and Their Role in Active Ingredient Sameness

Impurity Profiles in Active Ingredient Sameness help demonstrate API quality, equivalence, safety, and regulatory compliance.

resolvemass.ca
1
17
What causes peptide characterization projects to fail? Incomplete documentation. Clear sequences, purity specs & regulatory requirements help CROs deliver reliable LC-MS/MS results. Read more: resolvemass.ca/specification… #PeptideCharacterization #AnalyticalTesting #Pharma

What Documents and Specifications to Provide When Outsourcing Peptide Characterization to a CRO

Specifications to provide when Outsourcing Peptide Characterization CRO for accurate analysis, faster timelines, and compliance.

resolvemass.ca
1
3
POC GMP manufacturing demands more than synthesis—it requires robust analytics, impurity control & regulatory readiness. ResolveMass helps de-risk development. Read more: resolvemass.ca/gmp-manufactu… #PeptideOligonucleotideConjugates #AnalyticalTesting #Pharma

GMP Manufacturing of Peptide-Oligonucleotide Conjugates: What to Expect from a CRO

GMP Manufacturing of Peptide-Oligonucleotide Conjugates: Learn CRO capabilities, GMP processes, and testing requirements.

resolvemass.ca
1
23
🔬 PLLA, PDLA or PDLLA? PLA stereochemistry controls degradation, crystallinity & drug release. Learn the key differences: resolvemass.ca/pla-stereoche… #PLAStereochemistry #DrugDelivery

PLA Stereochemistry: PLLA vs PDLA vs PDLLA and Their Impact on Drug Delivery Performance

Learn PLA Stereochemistry: PLLA vs PDLA vs PDLLA and how polymer structure impacts drug delivery performance.

resolvemass.ca
2
16
🚨 Pharmacopoeial methods may miss nitrosamines at regulatory limits. Learn why LC-MS/MS & GC-MS/MS are essential for compliance and patient safety. Read more: resolvemass.ca/pharmacopoeia… #NitrosamineTesting

Can Existing Pharmacopoeial Methods Be Used for Nitrosamine Testing? Gaps and Limitations

Explore Pharmacopoeial Methods for Nitrosamine Testing, their limitations, analytical gaps, and regulatory challenges.

resolvemass.ca
1
5
🔬 Could chemicals from a transdermal patch impact patient safety? Learn how E&L testing identifies hidden risks and supports compliance. resolvemass.ca/extractables-… #TransdermalPatches #AnalyticalTesting #PharmaScience

Extractables and Leachables (E&L) Testing for Transdermal Patches and Topical Drug Delivery Systems

Extractables and Leachables (E&L) Testing for Transdermal Patches ensures safety, compliance, and product quality.

resolvemass.ca
1
3
FDA vs EMA biosimilar pathways aren't identical. Learn key differences in interchangeability, comparability, and clinical requirements for global success. Read more: resolvemass.ca/fda-vs-ema-bi… #Biosimilars #PharmaceuticalScience #FDAvsEMA

FDA vs EMA Biosimilar Regulatory Pathways: Key Differences and What They Mean for Your Programme

Compare FDA vs EMA Biosimilar Regulatory Pathways, key approval differences, interchangeability, and global strategy.

resolvemass.ca
1
3
🚀 Biosimilars aren't generics. They require extensive analytical similarity, PK/PD, and regulatory evidence. Explore our step-by-step Biosimilar Development Guide. Read more: resolvemass.ca/biosimilar-de… #BiosimilarDevelopmentGuide #AnalyticalTesting #Biopharma

What is Biosimilar Development? A Step-by-Step Guide from Molecule to Market

Biosimilar Development Guide: Learn the complete journey from molecule selection to regulatory approval and market launch.

resolvemass.ca
1
4
Is your peptide reference standard regulatory-ready? Identity, purity, potency & stability are critical for compliance. Read more: resolvemass.ca/peptide-refer… #PeptideReferenceStandardQualification #Pharma

Peptide Reference Standard Qualification: Analytical Requirements for Regulatory and Assay Use

Peptide Reference Standard Qualification: Learn analytical, regulatory, purity, identity, and stability requirements.

resolvemass.ca
1
3
Burst release can make or break a PLGA formulation. Surface drug, porosity & polymer design drive early dose dumping risks. ResolveMass explains mitigation strategies for LAIs & implants. Read more: resolvemass.ca/burst-release… #PLGA #AnalyticalTesting #PharmaceuticalScience

Understanding Burst Release in PLGA Formulations — Causes, Consequences, and Mitigation

Understand Burst release in PLGA Formulations, its causes, impact on drug delivery, and effective strategies to control it.

resolvemass.ca
1
4
🚨 Nitrosamine above the AI limit? Sponsors must act fast with testing, RCA, CAPA & regulatory reporting. Learn the key steps: resolvemass.ca/nitrosamine-e… #Nitrosamines #AnalyticalTesting

What Happens When a Nitrosamine Exceeds the Acceptable Intake Limit? Steps a Sponsor Must Take -

Introduction: When a nitrosamine exceeds the acceptable intake limit in a drug product or active pharmaceutical ingredient (API), it triggers […]

resolvemass.ca
3
🔬 Is your packaging impacting drug safety? E&L testing identifies packaging-related impurities and supports regulatory compliance. Read more: resolvemass.ca/extractables-… #ExtractablesAndLeachables #AnalyticalTesting

Extractables and Leachables (E&L) Testing for Container Closure Integrity Programs

Expert Extractables and Leachables Testing for Container Closure Systems to ensure drug safety, compliance, and quality.

resolvemass.ca
1
Why are Carmustine PLGA wafers analytically challenging? Drug stability, PLGA degradation, and release kinetics must be characterized together for reliable implant performance. Read more: resolvemass.ca/carmustine-pl… #CarmustinePLGA #AnalyticalTesting

Carmustine PLGA Wafer Characterization: Analytical Challenges in Solid Implant Drug Delivery Systems

Carmustine PLGA characterization: analytical challenges in implant drug delivery, release testing, degradation, and stability.

resolvemass.ca
1
4
Did you know Aripiprazole Lauroxil depots require tracking both PLGA degradation and prodrug conversion? ResolveMass explains the dual-kinetic challenge. Read more: resolvemass.ca/aripiprazole-… #Aripiprazole #PLGA #AnalyticalTesting

Aripiprazole Lauroxil Depot Characterization: Dual Complexity of Prodrug Conversion and PLGA...

Aripiprazole PLGA Depot Characterization: Analyze prodrug conversion, PLGA degradation, release kinetics, and stability.

resolvemass.ca
1
3
🔬 Insulin ANDA success requires more than bioequivalence. Peptide mapping, LC-MS/MS sequencing, HOS analysis, and impurity profiling are key to proving sameness. Learn more: resolvemass.ca/insulin-analo… #InsulinANDA #AnalyticalTesting #PharmaceuticalScience

Insulin Analog Characterization for Generic ANDA: Peptide Mapping, Sequencing, and Sameness Strategy

Insulin Analog Characterization for Generic ANDA using peptide mapping, sequencing, impurity profiling, and sameness studies.

resolvemass.ca
1
6
Can burst release in Naltrexone PLGA microspheres be controlled? ResolveMass reduced 24h burst from 31.2% to 6.4% through polymer design. Read more: resolvemass.ca/naltrexone-pl… #AnalyticalTesting #PharmaScience

Naltrexone PLGA Microsphere Case Study: Controlling Burst Release Through Polymer Design

Learn how Naltrexone PLGA Microsphere Burst Release was reduced through polymer design, process optimization, and characterization.

resolvemass.ca
1
4
High drug-load PLGA depots demand advanced analytics. Discover how HRMS/MS & LC-MS improve Buprenorphine PLGA Depot Characterization for safer injectables. Read more: resolvemass.ca/buprenorphine… #AnalyticalTesting #PharmaceuticalScience

Buprenorphine Depot PLGA Characterization: High Drug Load Challenges in Long-Acting Injectables -

Summary: 1: Introduction: Buprenorphine PLGA Depot Characterization is critical for the development of long-acting injectable formulations intended for opioid dependence […]

resolvemass.ca
1
5
Glycopeptide Characterization is key to understanding glycan heterogeneity, stability & biosimilarity in therapeutics. Explore LC-MS/MS, HCD & ETD workflows: resolvemass.ca/glycopeptide-… #GlycopeptideCharacterization #AnalyticalTesting

Glycopeptide Characterization: Analytical Approaches for Glycosylated Therapeutic Peptides

Glycopeptide Characterization using advanced LC-MS techniques for accurate glycan profiling and therapeutic peptide analysis.

resolvemass.ca
7
🚨 Disulfide Bond Mapping is critical for peptide stability & safety. Learn how LC-MS and ETD improve structural characterization. Read more: resolvemass.ca/disulfide-bon… #DisulfideBondMapping #AnalyticalTesting

Disulfide Bond Mapping in Therapeutic Peptides: LC-MS Strategies and Analytical Challenges -

Introduction: Disulfide Bond Mapping in Therapeutic Peptides is a critical analytical process used to verify the structural integrity and biological […]

resolvemass.ca
1
6
Load more